Sulfur mustard-induced neutropenia: Treatment with granulocyte colony-stimulating factor

Military Medicine

Volumn 171, Issue 5, 2006, Pages 448-453

  Anderson, Dana R ^a   Holmes, Wesley W ^a   Lee, Robyn B ^a   Dalal, Stephen J ^a   Hurst, Charles G ^a   Maliner, Beverly I ^a   Newmark, Jonathan ^a   Smith, William J ^a  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; MUSTARD GAS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; CHEMICAL WARFARE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; EPITHELIUM CELL; LEUKOCYTE COUNT; LYMPHATIC SYSTEM; MEGAKARYOCYTE; MONKEY; NEUTROPENIA; NONHUMAN; RECOMBINANT DNA TECHNOLOGY;

EID: 33646566807     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED.171.5.448     Document Type: Article

References (27)

1. Papirmeister B, Feister AJ, Robinson SI, Ford RD: Medical Defense Against Mustard Gas: Toxic Mechanisms and Pharmacological Implications. Boca Raton, FL. CRC Press, 1991.
2. Pauser G, Alloy A, Carvana M, et al: Lethal intoxication by wargases on Iranian soldiers: therapeutic interventions on survivors of mustard gas and mycotoxin inmersion. In: Proceedings of the First World Congress: New Compounds in Biological and Chemical Warfare: Toxicological Evaluation. pp 341-51. Ghent, Belgium, Faculty of Pharmaceutical Sciences, State University of Ghent, and the National Science Foundation of Belgium, 1984.
3. Mandl H, Freilinger G: First report on victims of chemical warfare in the Gulf-War treated in Vienna. In: Proceedings of the First World Congress: New Compounds in Biological and Chemical Warfare: Toxicological Evaluation, pp 330-40. Ghent, Belgium, Faculty of Pharmaceutical Sciences, State University of Ghent, and the National Science Foundation of Belgium, 1984.
4. Merz DF, Anderson DR: Cytoprotective effect of mesna treatment for sulfur mustard (HD) induced lung injury. FASEB J 2001; 15: A925.
5. Gold MB, Scharf B: Hematological profile of the euthymic hairless guinea pig following sulfur mustard vesicant exposure. J Appl Toxicol 1995; 15: 433-8.
6. Meisenberg BR, Davis TA, Melaragno AJ, Stead R, Monroy RL: A comparison of therapeutic schedules for administering granulocyte colony-stimulating factor to nonhuman primates after high-dose chemotherapy. Blood 1992; 79: 2267-72.
7. Tabarra IA: Granulocyte colony-stimulating factor. South Med J 1993; 86: 350-5.
8. Zamboni WC: Pharmacokinetics of pegfilgrastim. Pharmacotherapy 2003; 23: 9S-14S.
9. Bronchud MH, Scarffe JH, Thatcher N, et al: Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987; 56: 809.
10. Morstyn G, Souza LM, Keech J, et al: Effect of granulocyte-colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 1: 667.
11. Welte K, Bonilla MA, Garbilove JL, et al: Recombinant human granulocyte-colony stimulating factor: in vitro and in vivo effects on myelopoiesis. Blood Cells 1987; 13: 17-30.
12. Crawford J, George M: The role of hematopoietic growth factors in support of ifosamide/carboplatin/etoposide chemotherapy. Semin Oncol 1995; 22(Suppl 7): 18-22.
13. Meisenberg BR, Monroy RL, Melaragno AJ: Granulocyte colony stimulating factor (G-CSF) for mustard-induced bone marrow suppression. Milit Med 1993; 158: 470-4.
14. Pechura CM, Rall DP (editors): Veterans at Risk: The Health Effects of Mustard Gas and Lewisite, Washington, DC, National Academy Press, 1993.
15. Kindred JE: The blood cells and hemopoietic and other organs of dogs given intravenous injections of 2-chloroethyl vesicants. Arch Pathol 1949; 47: 378-98.
16. Rappeneau S, Baeza-Squiban A, Marano F, Calvet J: Efficient protection of human bronchial epithelial cells against sulfur mustard and nitrogen mustard cytotoxicity using drug combinations. Toxicol Sci 2000; 58: 153-60.
17. Gray P, Lewis K, Masta A, Phillips D: Modulation of mustard toxicity by tacrine. Biochem Pharmacol 1994; 47: 581-3.
18. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony stimulating factors: evidence-based, clinical practical guidelines. J Clin Oncol 2000; 18: 3558-85.
19. Hartley C, McElroy T, Sunderland W, Molineaux G: Treatment with SD/01 relative to chemotherapy in mice. #Abstr Exp Hematol 2000; 31: 131.
20. Mucenski JW, Shogan JE: Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor. J Manage Care Pharm 2003; 9(Suppl): 10-4.
21. Crawford J: Once per cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 2003; 30(Suppl 13): 24-30.
22. Bronchud MH: The importance of dose in cancer chemotherapy and the role of hematopoietic growth factors. In: Filgrastim (r-metHuG-CSF) in Clinical Practice, pp 165-209. Edited by Morstyn G, Dexter TM, Foote M. New York, Marcel Dekker, 1998.
23. Willems JL: Clinical management of mustard gas casualties. Ann Med Milit Belg 1989; 3: S1-61.
24. Sidell FR, Hurst CG: Clinical considerations in mustard poisoning. In: Chemical Warfare Agents, pp 51-66. Edited by Somani SM, San Diego, CA, Academic Press, 1992.
25. Russell AR, Davies EG, Ball SE, Gordon-Smith E: Granulocyte colony stimulating factor treatment for neonatal neutropenia. Arch Dis Child Fetal Neonatal Ed 1995; 72: 53-4.
26. Molineaux G, Dexter TM: Biology of G-CSF. In: Filgrastim (r-metHuG-CSF) in Clinical Practice, pp 1-39. Edited by Morstyn G, Dexter TM, Foote M. New York, Marcel Dekker, 1998.
27. Harker LA, Marzec UM, Kelly AB, et al: Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony stimulating factor. Blood 1997; 89: 155-65.